Mutation status and surgical selection

Current evidence cannot support denying metastasectomy in otherwise resectable patients solely based on their overall KRAS or BRAF mutational status. The combination of KRAS or BRAF mutational status with certain clinicopathologic characteristics has defined groups of patients who may not derive benefit from metastasectomy, but external validation is needed. The effect of certain KRAS or BRAF variants on survival may be more pronounced and therefore future studies should consider them for surgical selection.

[1]  J. Spicer,et al.  Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations. , 2019, Annals of surgery.

[2]  V. Whitehall,et al.  How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications , 2018, Gastroenterology research and practice.

[3]  J. Vauthey,et al.  ASO Author Reflections: RAS Mutations in Metastatic Colorectal Cancer , 2018, Annals of Surgical Oncology.

[4]  Yuhree Kim,et al.  Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases , 2018, The British journal of surgery.

[5]  P. Lønning,et al.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer , 2018, JAMA surgery.

[6]  J. Vauthey,et al.  RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases , 2018, Annals of Surgical Oncology.

[7]  P. Lønning,et al.  Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. , 2018, Anticancer research.

[8]  R. Yaeger,et al.  Colorectal cancer genomics and designing rational trials. , 2018, Annals of translational medicine.

[9]  M. Choti,et al.  Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases , 2017, Annals of surgery.

[10]  O. Lichtarge,et al.  Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases , 2017, Annals of surgery.

[11]  J. Shindoh,et al.  RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases , 2017, Annals of surgery.

[12]  M. Kendrick,et al.  Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. , 2017, The oncologist.

[13]  Jesse S. Voss,et al.  Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Mountford,et al.  Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer , 2017, British Journal of Cancer.

[15]  J. Vauthey,et al.  Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection , 2017, Surgery.

[16]  Yuhree Kim,et al.  Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases , 2016, Cancer.

[17]  T. Pawlik,et al.  From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. , 2016, Surgical oncology.

[18]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. Russo,et al.  Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.

[20]  M. Choti,et al.  Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer , 2016, Annals of Surgical Oncology.

[21]  J. Shindoh,et al.  KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion , 2016, Annals of Surgical Oncology.

[22]  J. Vauthey,et al.  Meta‐analysis of KRAS mutations and survival after resection of colorectal liver metastases , 2015, The British journal of surgery.

[23]  M. Choti,et al.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. , 2015, JAMA surgery.

[24]  V. Heinemann,et al.  KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. , 2015, Future oncology.

[25]  G. Fontanini,et al.  BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Choti,et al.  Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases , 2015, Annals of Surgical Oncology.

[27]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[28]  M. D'Angelica,et al.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases , 2014, Cancer.

[29]  M. Ladanyi,et al.  BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.

[30]  Mef Nilbert,et al.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.

[31]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[32]  D. Lambrechts,et al.  Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab , 2013, Clinical Cancer Research.

[33]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[35]  Roger Berry,et al.  KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer , 2011, Clinical Cancer Research.

[36]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[37]  J. Neumann,et al.  Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. , 2009, Pathology, research and practice.

[38]  T. Takada,et al.  A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. , 2004, Journal of hepato-biliary-pancreatic surgery.

[39]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[40]  T. Starzl,et al.  Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. , 1999, Journal of the American College of Surgeons.

[41]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[42]  P. Lønning,et al.  Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients. , 2019, Annals of surgery.

[43]  I. Endo,et al.  The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors , 2018, Annals of surgery.

[44]  M. Gönen,et al.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. , 2018, Annals of surgery.

[45]  Bradford J. Kim,et al.  Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? , 2017, Annals of Surgical Oncology.